Right Phrenic Nerve Localization on CT for Ablation

January 5, 2026 updated by: Antonio Berruezo, MD, PhD, Centro Medico Teknon

Right Phrenic Nerve Localization Using CT Scanning: Implications for Radiofrequency Ablation Procedures

The anatomical location of the right phrenic nerve (RPN) in close proximity to the right pulmonary veins has become a critical consideration for electrophysiologists performing pulmonary vein isolation, the cornerstone treatment for atrial fibrillation. Although radiofrequency ablation in this region is rarely associated with complications-unlike cryoballoon ablation-the proximity of the RPN to the ablation site is considered the most widely accepted mechanism of nerve injury. Therefore, accurately defining its anatomical course is essential to prevent complications.

This concern extends to any ablation procedure performed near the RPN, including those targeting the lateral-posterior region of the right atrium, particularly during atrial tachycardia ablation or cardioneuroablation. Several methods have been used to precisely localize the RPN. The most commonly employed technique is phrenic nerve stimulation; however, there is growing interest in the use of computed tomography (CT) to identify structures running parallel to the nerve-such as the pericardiophrenic artery and vein-enhanced with contrast. Three-dimensional reconstruction through image segmentation has proven useful in defining the anatomy of cardiac chambers and adjacent extracardiac structures.

This study aims to compare two approaches for visualizing the course of the right phrenic nerve: one based on computed tomography imaging and the other on the nerve's response to stimulation during the procedure. This comparison will allow us to assess the concordance between imaging findings and intra-procedural observations, ultimately contributing to improved procedural safety.

Study Overview

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Barcelona
      • Barcelona, Barcelona, Spain, 08022
        • Antonio Berruezo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All patients underwent an electrocardiography-gated cardiovascular CT using a 64-slice multidetector row CT scanner (Revolution CT, GE Healthcare Global Diagnostic Imaging) prior to the ablation procedure. The position line was set at 0.5 cm below the tracheal bifurcation to the cardiac diaphragmatic surface. The acquisition was performed within a single breath- hold. The gantry rotation time was 0.35 s, and the tube current was 350-750 mA at 120 kV. Iodinated contrast material (60 mL; Omnipaque 300 mg/mL), was injected at a rate of 4-5 mL/s, followed by 20 mL of saline solution. A second acquisition immediately after is performed to study the venous phase. Original images at 75% or 45% R-R intervals were transferred to post-processing Workstation, with a section thickness of 0.625 mm. If motion artifacts appeared, the electrocardiographic editing technique was used and the reconstructed window was moved forward or backward for 5% R-R interval until the motion artifacts disappeared.

Description

Inclusion Criteria:

  • Ability to provide informed consent
  • Patients who have undergone or will undergo transcatheter AF ablation or CNA
  • Availability of 64-slice contrast-enhanced MDCT with RPN segmentation using ADAS® software prior to ablation
  • Age ≥ 18 years

Exclusion Criteria:

  • Inability to provide informed consent
  • Inability to perform contrast-enhanced CT before transcatheter AF ablation or CNA
  • Age < 18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
This study will enroll patients undergoing two distinct types of ablative procedures g

A total of 80 consecutive patients will be included:

  • 60 patients will be enrolled using a single electric stimulation output set at 20 mA, 2 ms amplitude width and 1000 ms cycle length
  • 20 patients will be enrolled using a double electric stimulation output set respectively at 10 mA and 20 mA (2 ms amplitude width and 1000 ms cycle length)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
analyse the anatomy of the RPN
Time Frame: From January 2021 to April 2025
The primary endpoint of this study is to analyse the anatomy of the RPN using three-dimensional (3D) imaging and iso-distance mapping with ADAS® software, and to validate its accuracy through traditional pace mapping.
From January 2021 to April 2025
Accuracy of Imaging-Guided Anatomical Localization of the Phrenic Nerve with ADAS® software Compared With Conventional Pacemapping
Time Frame: from the procedure to 12 months later
The positions as observed by the 2 different methods are compared and the correlation was expressed as a percentage. Global image correlation is computed as the mean correlation between methods.
from the procedure to 12 months later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2025

Primary Completion (Actual)

September 20, 2025

Study Completion (Actual)

September 29, 2025

Study Registration Dates

First Submitted

December 10, 2025

First Submitted That Met QC Criteria

January 5, 2026

First Posted (Actual)

January 9, 2026

Study Record Updates

Last Update Posted (Actual)

January 9, 2026

Last Update Submitted That Met QC Criteria

January 5, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe